Announcements
Sidley Represents CKD Pharma in US$1.3 Billion Out-license of Its Proprietary Therapeutic to Novartis
November 10, 2023
Largest ever out-licensing deal for the South Korean pharmaceutical company and largest deal for the Korean pharmaceutical industry this year
A cross-disciplinary team of Sidley lawyers represented Chong Kun Dang Corp. (CKD) in a potentially US$1.3 billion out-licensing of its proprietary therapeutic to Novartis AG. The transaction grants Novartis the rights to develop and commercialize CKD-510, an HDAC6 inhibitor. CKD had completed Phase I trials of CKD-510 in Europe for Charcot-Marie-Tooth (CMT) disease, a genetic nerve disorder.
Under the terms of the agreement, Novartis will pay CKD an upfront fee of US$80 million, milestone fees of up to US$1.2 billion over time per the drug’s development, approval, and sales successes, as well as separate royalties for its sale.
BioCentury reported this as one of the largest out-licensing transactions in the last five years in Korea. Of the eight transactions BioCentury sampled since the beginning of 2019, Sidley has represented the Korean licensors in four of the transactions.
The Sidley team was led by Life Sciences Transactions lawyers Joshua Hofheimer (Century City), Jean Qiu (Shanghai), and Sabrina Glavota (Century City) and included support from Sue Wang (IP Litigation, San Francisco); Scott Kaplan and Kelly Cho (Food Drug and Medical Device, Washington, D.C.); Matt Clemente (Restructuring, Chicago); and James W. Lowe, Edward W. Sharon, and Miriam Carroll Silvestri (Antitrust and Competition, Washington, D.C.).
A cross-disciplinary team of Sidley lawyers represented Chong Kun Dang Corp. (CKD) in a potentially US$1.3 billion out-licensing of its proprietary therapeutic to Novartis AG. The transaction grants Novartis the rights to develop and commercialize CKD-510, an HDAC6 inhibitor. CKD had completed Phase I trials of CKD-510 in Europe for Charcot-Marie-Tooth (CMT) disease, a genetic nerve disorder.
Under the terms of the agreement, Novartis will pay CKD an upfront fee of US$80 million, milestone fees of up to US$1.2 billion over time per the drug’s development, approval, and sales successes, as well as separate royalties for its sale.
BioCentury reported this as one of the largest out-licensing transactions in the last five years in Korea. Of the eight transactions BioCentury sampled since the beginning of 2019, Sidley has represented the Korean licensors in four of the transactions.
The Sidley team was led by Life Sciences Transactions lawyers Joshua Hofheimer (Century City), Jean Qiu (Shanghai), and Sabrina Glavota (Century City) and included support from Sue Wang (IP Litigation, San Francisco); Scott Kaplan and Kelly Cho (Food Drug and Medical Device, Washington, D.C.); Matt Clemente (Restructuring, Chicago); and James W. Lowe, Edward W. Sharon, and Miriam Carroll Silvestri (Antitrust and Competition, Washington, D.C.).
Contacts
*Qualified in the P.R.C. but does not hold a current P.R.C. practicing certificate.
Offices
Capabilities
Suggested News & Insights
Sidley Ranked in Chambers Greater China Region 2026January 15, 2026Korea Night @ JPM 2026Wednesday, January 14, 2026Global IR Pitching @ JPM 2026 (Co-hosted by KoreaBIO and Sidley)Tuesday, January 13, 2026Recharge & Recaffeinate with Sidley @ JPMMonday, January 12, 2026 – Tuesday, January 13, 2026Biotech Dealmaking – Regulatory Considerations for the Next Wave of Development-Stage Transactions – Program and Lunch @ JPM 2026Monday, January 12, 2026Connecting Clusters of Excellence: Europe as Your Gateway to Global Success – Organized by Biovia, Health Campus Limburg DC, SidleyMonday, January 12, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory